Analyst
Barclays
Equibles does not estimate personal net worth.
Ellie Merrill is recorded as Analyst at Barclays. Ellie Merrill has spoken on 3 earnings calls across 3 companies, most recently for Moderna, Inc. on July 31, 2026. Those appearances were for Moderna, Inc. (MRNA), Ultragenyx Pharmaceutical Inc. (RARE) and Sarepta Therapeutics, Inc. (SRPT). The companies whose calls Ellie Merrill spoke on are classified in the Healthcare sector.
“Just can you give us any more color on how we should think about the timelines for getting data from the Aurora study, and if the data are positive in the Phase III ASPIRE trial, how are you thinking about what your base case will be for the ages in a potential Angelman label, and if this will include adults?”
“This is Josh Fleischman on the line for Ritu. We send our best wishes to you and your family, and thank you for taking our question. How strong has physician and patient interest been in Endeavor Cohort 8 recruitment, and can you give any color on the current extent of enrollment?”
Barclays
Analyst
Transcript header (unverified)
MRNA
Biotechnology · Healthcare
